Internal Med Medical News about hyperphosphataemia

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

5. Rapid correction of low vitamin D status in nursing home residents

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Effect of MCI-196 on serum phosphate and cholesterol levels in haemodialysis patients with hyperphosphataemia: a double-blind, randomized, placebo-controlled study
Nephrology Dialysis Transplantation, 09/14/09

Locatelli F et al. – MCI–196 significantly reduced serum phosphorus, Ca x P and PTH, without effecting serum calcium levels. The additional reduction in total cholesterol and LDL cholesterol indicates a possible dual mechanism of action of MCI–196 that has the potential to reduce cardiovascular morbidity in CKD stage 5 patients.

Exclusive Author Commentary
Francesco Locatelli, 09/17/09

Pharmacological and clinical research has been very active in the last decade in developing new phosphate binders. We conducted a randomized placebo-controlled trial in CKD stage 5 patients that demonstrated the short-term efficacy and safety of MCI-196, a new calcium-free-metal-free phosphate binder. Moreover MCI-196 brings a significant reduction in cholesterol plasma levels and this ,in addition to phosphate and calcium control, may help to further reduce the cardiovascular risk of CKD patients. Other studies are underway to better characterize the safety profile and long-term effectiveness in controlling calcium phosphate metabolism and also in the lipids control of MCI-196. Therefore there are good prospects that the family of phosphate binders will be extended to new agents such as MCI-196 shortly and this would hopefully help to improve therapy for stage 5 CKD patients.

<< Previous
A Multi-Institutional Phase II Study of the Efficacy and...

Next >>
Percentage of Positive Biopsy Cores at the Onset of Hormone...